Search

BioCryst Pharmaceuticals Inc

Cerrado

SectorSanidad

8.23 1.48

Resumen

Variación precio

24h

Actual

Mínimo

8.08

Máximo

8.36

Métricas clave

By Trading Economics

Ingresos

800M

78M

Ventas

62M

218M

P/B

Media del Sector

7.603

56.597

BPA

0.3

Margen de beneficios

35.92

Empleados

435

EBITDA

799M

99M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+149.04% upside

Dividendos

By Acuity

Próximas Ganancias

2 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

306M

2.5B

Apertura anterior

6.75

Cierre anterior

8.23

Noticias sobre sentimiento de mercado

By Acuity

54%

46%

262 / 339 Clasificación en Healthcare

BioCryst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 sept 2026, 20:08 UTC

Macro Event

BioCryst Pharmaceuticals Inc is lower today, continuing a seven-session decline amid macroeconomic data showing inflation rates in line with expectations.

10 sept 2026, 23:26 UTC

No specific news was identified for BioCryst Pharmaceuticals Inc. in after-market trading. Shares remained effectively flat since Thursday's close.

9 sept 2026, 23:46 UTC

BioCryst Pharmaceuticals Inc. shares are higher in after-market trading, despite a generally flat performance and remaining below their 20-day moving average.

8 sept 2026, 23:16 UTC

BioCryst Pharmaceuticals shares are higher in after-market hours, despite four consecutive lower closes. No specific news was identified to explain the price movement.

3 sept 2026, 20:07 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a decline since Wednesday. No specific news has been identified to explain the movement.

2 sept 2026, 23:46 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market hours. No specific news was identified to explain the decline amid broader market sentiment shifts.

1 sept 2026, 22:26 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market hours following a stable performance. No specific news was identified to explain the price movement.

31 ago 2026, 20:07 UTC

BioCryst Pharmaceuticals Inc shares are lower today amid broader market declines following inflation concerns from the Jackson Hole Economic Symposium.

28 ago 2026, 19:16 UTC

News

BioCryst Pharmaceuticals shares are lower despite reporting Q2 2026 revenue of $218.3 million, reflecting broader market trends and valuation discounts.

27 ago 2026, 20:07 UTC

BioCryst Pharmaceuticals shares are higher as positive jobless claims data boosts market sentiment. The stock stabilized after reaching a session high.

26 ago 2026, 19:36 UTC

Event

BioCryst Pharmaceuticals received marketing approval for ORLADEYO in pediatric patients. Shares are lower today amid broader market trends and inflation data.

24 ago 2026, 19:26 UTC

BioCryst Pharmaceuticals Inc shares are trading higher, maintaining a position above the 20-day moving average and near the midpoint of their one-month range.

21 ago 2026, 22:26 UTC

BioCryst Pharmaceuticals shares moved higher in after-hours trading, reaching a session high before slightly retracing. No specific news was identified to explain the movement.

20 ago 2026, 20:01 UTC

Correlated Moves
Social Media

BioCryst Pharmaceuticals Inc shares are lower amid a decline in the Biotechnology sub-sector. Earlier in the session, shares rebounded from a session high.

19 ago 2026, 23:01 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, retracing from an earlier uptick with no specific news identified to explain the decline.

18 ago 2026, 20:06 UTC

BioCryst Pharmaceuticals Inc shares are declining amid broader market weakness, with no specific news identified to explain today's price movement.

14 ago 2026, 19:06 UTC

BioCryst Pharmaceuticals is lower today, following broader market concerns over an unexpected drop in U.S. retail sales impacting Federal Reserve interest rate policy.

13 ago 2026, 21:31 UTC

BioCryst Pharmaceuticals shares traded roughly flat in after-market hours, remaining within their one-month range and above the 20-day moving average.

12 ago 2026, 19:41 UTC

BioCryst Pharmaceuticals shares are higher today, rebounding from an earlier dip and reflecting notable volatility during the session. The stock remains above its 20-day moving average.

11 ago 2026, 23:26 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Tuesday's close amid broader market weakness and cautious sentiment.

10 ago 2026, 19:51 UTC

News

BioCryst Pharmaceuticals Inc. shares are higher after Wall Street Zen upgraded its rating to "strong-buy." Other firms also adjusted price targets amid market uncertainty.

7 ago 2026, 19:56 UTC

BioCryst Pharmaceuticals is trading higher, continuing a positive trend amid easing concerns over interest rate hikes following a disappointing jobs report.

6 ago 2026, 22:36 UTC

BioCryst Pharmaceuticals shares are lower in after-market trading, continuing a decline since Thursday's close and positioned below the 20-day moving average.

5 ago 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, despite no specific news identified to explain the movement. They remain below their 20-day moving average.

4 ago 2026, 19:36 UTC

Correlated Moves

BioCryst Pharmaceuticals Inc shares are higher today, supported by gains in the biotechnology sector. The stock remains above its earlier low despite recent trends.

3 ago 2026, 19:56 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a downward trend since Friday. The broader market is seeing gains, contrasting with BioCryst's performance.

31 jul 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading. No specific news was identified to explain this movement, reflecting routine performance since Friday's close.

30 jul 2026, 20:09 UTC

BioCryst Pharmaceuticals shares are lower amid broader market volatility following mixed economic signals, including rising jobless claims and disappointing GDP growth.

29 jul 2026, 19:35 UTC

BioCryst Pharmaceuticals Inc shares are lower amid a declining market, with no specific company news identified to explain the movement during today's session.

28 jul 2026, 23:06 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, continuing an upward trend from Tuesday's close, despite an earlier session pullback.

Comparación entre iguales

Cambio de precio

BioCryst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

149.04% repunte

Estimación a 12 Meses

Media 20.222 USD  149.04%

Máximo 32 USD

Mínimo 11 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

7

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

262 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
help-icon Live chat